A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
A phase 3 trial of Doxorubicin, Pegylated liposomal doxorubicin, Topotecan, Gemcitabine, Pembrolizumab and Bevacizumab in ovarian cancer, run by GlaxoSmithKline, now recruiting.
Overview
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) is a phase 3 interventional study registered as NCT07286266 by GlaxoSmithKline, with 450 participants planned, started 2026-06-18 and due to reach its primary completion in 2029-12-17. Interventions recorded: Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD), Topotecan, Gemcitabine and Pembrolizumab.
Similar pages
not linked directly; found by shared links- TrialMirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
Shares Pegylated liposomal doxorubicin, Doxorubicin, Gemcitabine, Ovarian cancer and the tag pipeline.
- TrialA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
- TrialA Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Shares GSK, Doxorubicin and the tag pipeline.
- TrialA Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Shares GSK, Bevacizumab and the tag pipeline.
- TrialA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Shares GSK, Ovarian cancer and the tag pipeline.
- TrialA Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
Shares GSK, Pembrolizumab and the tag pipeline.
- TrialA Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
Shares GSK, Pembrolizumab and the tag pipeline.
- TrialA Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Shares GSK, Ovarian cancer and the tag pipeline.